Definium Therapeutics (DFTX) Insider & Congress Trades

Smart money at a glance

Filings to Oct 27, 2026

Net selling: insiders sold $3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$3M netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 2 added, 0 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about DFTX filings

Are insiders buying or selling Definium Therapeutics, Inc. (DFTX) stock?

Net selling: insiders sold $3M and bought $0 of DFTX stock on the open market in the 90 days to Oct 27, 2026, according to SEC Form 4 filings. $3M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Barrow, Robert (Chief Executive Officer), who sold $1.9M. The latest filing was on Sep 30, 2026.

Which members of Congress have traded DFTX recently?

None. No member of Congress disclosed a DFTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this DFTX smart-money data?

This summary uses filings available on Oct 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on DFTX

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $2.1M
3 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about DFTX filings

Are insiders buying or selling Definium Therapeutics, Inc. (DFTX) stock?

Which members of Congress have traded DFTX recently?

None. No member of Congress disclosed a DFTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this DFTX smart-money data?

Funds

What funds are doing

7 moves · 6 mo

Buys/Adds$479.8MSells/Trims$17.1M

Buys/Adds (3)

QR
Qube Research
Q2 2026 13F
$24.1M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%
FM
FMR LLC
Q2 2026 13F
$189.4M
added
SS
State Street
Q1 2026 13F
$46.7M
bought
Signals like this: n=3224, 54% finished lower at D15, median -0.8% vs SPY -0.4%

4 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 4 moves

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 6, 2026

Earnings came in $0.89 a share below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 6, 2026

Period ending

Jun 30, 2026

Earnings per share

-$1.44-$0.89 miss

-$0.55 expected

Revenue

$0.00

SEC filing · No operating revenue

EPS: Yahoo Finance

Next report

Estimated report: Nov 5, 2026, in 9 days

Previous reports

Period ending	Reported	EPS / estimate	EPS surprise	Revenue / income	Surprise
Jun 30, 2026	Aug 6, 2026	-$1.44 / -$0.55Yahoo Finance	-$0.89 miss	$0.00 No estimateSEC filing · No operating revenue	Unavailable
Mar 31, 2026	May 7, 2026	-$0.71 / -$0.49Yahoo Finance	-44.02% miss	$0.00 No estimate	Unavailable
Dec 31, 2025	Feb 26, 2026	-$0.50 / -$0.49Yahoo Finance	-2.04% miss	$0.00 No estimate	Unavailable
Sep 30, 2025	Nov 6, 2025	-$0.78 / -$0.50Yahoo Finance	-54.84% miss	$0.00 No estimate	Unavailable
Jun 30, 2025	Jul 31, 2025	-$0.50 / -$0.36Alpha Vantage	-38.89% miss	Unavailable	Unavailable
Mar 31, 2025	May 8, 2025	-$0.35 / -$0.37Alpha Vantage	+5.41% beat	Unavailable	Unavailable
Dec 31, 2024	Mar 6, 2025	-$0.41 / -$0.31Alpha Vantage	-32.26% miss	Unavailable	Unavailable
Sep 30, 2024	Nov 7, 2024	-$0.18 / -$0.26Alpha Vantage	+30.77% beat	Unavailable	Unavailable

EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.

Open: $35.60
52-wk high: $49.70
High: $36.35
52-wk low: $10.46
Low: $34.74
Prev close: $35.67
Mkt cap: $4.79B
ROE: -64.1%
Beta: 2.19
P/B: 5.0x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $4.8B

Valuation

P/B5.02

Quality

Operating margin0.0%
ROE-64.1%
ROA-20.6%

Growth

Beta2.19

Technicals

Price structure

This stock is trending upward.

Trend

Constructive

60 / 100

RSI 14

50balanced

20D volatility

52%annualized

52-week range

$35.68

$10.46$49.70

20D support

$32.02recent floor

20D resistance

$38.95recent ceiling

Returns

5D +8.2%20D -7.1%60D -18.0%

Price vs moving averages

SMA20 +0.5%SMA50 -7.2%SMA200 +22.4%

Volume pace

0.85xvs prior 20D

Smart money at a glance

Filings to Oct 27, 2026

Net selling: insiders sold $3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$3M netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, quarter ended Jun 30, 2026: 2 added, 0 cutMore adding
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about DFTX filings

Are insiders buying or selling Definium Therapeutics, Inc. (DFTX) stock?

Which members of Congress have traded DFTX recently?

None. No member of Congress disclosed a DFTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this DFTX smart-money data?

13F: filed up to 45 days late.

Smart money on DFTX

Lean long1 source:
- Funds
Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $2.1M
3 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
Lean long3 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about DFTX filings

Are insiders buying or selling Definium Therapeutics, Inc. (DFTX) stock?

Which members of Congress have traded DFTX recently?

None. No member of Congress disclosed a DFTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this DFTX smart-money data?

Funds

What funds are doing

7 moves · 6 mo

Buys/Adds$479.8MSells/Trims$17.1M

Buys/Adds (3)

QR
Qube Research
Q2 2026 13F
$24.1M
added
Signals like this: n=13770, 53% finished lower at D15, median -0.4% vs SPY -0.4%
FM
FMR LLC
Q2 2026 13F
$189.4M
added
SS
State Street
Q1 2026 13F
$46.7M
bought
Signals like this: n=3224, 54% finished lower at D15, median -0.8% vs SPY -0.4%

4 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 4 moves

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 6, 2026

Earnings came in $0.89 a share below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 6, 2026

Period ending

Jun 30, 2026

Earnings per share

-$1.44-$0.89 miss

-$0.55 expected

Revenue

$0.00

SEC filing · No operating revenue

EPS: Yahoo Finance

Next report

Estimated report: Nov 5, 2026, in 9 days

Previous reports

Period ending	Reported	EPS / estimate	EPS surprise	Revenue / income	Surprise
Jun 30, 2026	Aug 6, 2026	-$1.44 / -$0.55Yahoo Finance	-$0.89 miss	$0.00 No estimateSEC filing · No operating revenue	Unavailable
Mar 31, 2026	May 7, 2026	-$0.71 / -$0.49Yahoo Finance	-44.02% miss	$0.00 No estimate	Unavailable
Dec 31, 2025	Feb 26, 2026	-$0.50 / -$0.49Yahoo Finance	-2.04% miss	$0.00 No estimate	Unavailable
Sep 30, 2025	Nov 6, 2025	-$0.78 / -$0.50Yahoo Finance	-54.84% miss	$0.00 No estimate	Unavailable
Jun 30, 2025	Jul 31, 2025	-$0.50 / -$0.36Alpha Vantage	-38.89% miss	Unavailable	Unavailable
Mar 31, 2025	May 8, 2025	-$0.35 / -$0.37Alpha Vantage	+5.41% beat	Unavailable	Unavailable
Dec 31, 2024	Mar 6, 2025	-$0.41 / -$0.31Alpha Vantage	-32.26% miss	Unavailable	Unavailable
Sep 30, 2024	Nov 7, 2024	-$0.18 / -$0.26Alpha Vantage	+30.77% beat	Unavailable	Unavailable

Open: $35.60
52-wk high: $49.70
High: $36.35
52-wk low: $10.46
Low: $34.74
Prev close: $35.67
Mkt cap: $4.79B
ROE: -64.1%
Beta: 2.19
P/B: 5.0x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $4.8B

Valuation

P/B5.02

Quality

Operating margin0.0%
ROE-64.1%
ROA-20.6%

Growth

Beta2.19

Technicals

Price structure

This stock is trending upward.

Trend

Constructive

60 / 100

RSI 14

50balanced

20D volatility

52%annualized

52-week range

$35.68

$10.46$49.70

20D support

$32.02recent floor

20D resistance

$38.95recent ceiling

Returns

5D +8.2%20D -7.1%60D -18.0%

Price vs moving averages

SMA20 +0.5%SMA50 -7.2%SMA200 +22.4%

Volume pace

0.85xvs prior 20D

Definium Therapeutics, Inc.

Smart money at a glance

What do analysts expect?

Questions about DFTX filings

Smart money on DFTX

Questions about DFTX filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in $0.89 a share below what analysts expected.

Estimated report: Nov 5, 2026, in 9 days

Previous reports

Is the business strong?

Price structure

Definium Therapeutics, Inc.

Smart money at a glance

What do analysts expect?

Questions about DFTX filings

Smart money on DFTX

Questions about DFTX filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in $0.89 a share below what analysts expected.

Estimated report: Nov 5, 2026, in 9 days

Previous reports

Is the business strong?

Price structure

Definium Therapeutics, Inc.

Overview

Questions about DFTX filings

Smart money

Unlock everything for $29/month

Earnings

Financials

Technicals

Definium Therapeutics, Inc.

Overview

Questions about DFTX filings

Smart money

Unlock everything for $29/month

Earnings

Financials

Technicals